Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
TLO 5.37 +5.7% BNKR 4.88 +1.7% GG 2.25 +3.2% MJS 0.100 +5.3% PAAS 62.54 +3.6% PE 0.230 +0.0% SGML 17.19 +4.8% LAR 10.34 −1.1% NED 0.025 +0.0% GEN 0.080 +0.0% TVI 0.060 +0.0% SKYG 0.025 −37.5% WRLG 0.660 +6.5% FFU 0.120 −7.7% LOD 0.310 +3.3% CBI 0.110 +0.0% TLO 5.37 +5.7% BNKR 4.88 +1.7% GG 2.25 +3.2% MJS 0.100 +5.3% PAAS 62.54 +3.6% PE 0.230 +0.0% SGML 17.19 +4.8% LAR 10.34 −1.1% NED 0.025 +0.0% GEN 0.080 +0.0% TVI 0.060 +0.0% SKYG 0.025 −37.5% WRLG 0.660 +6.5% FFU 0.120 −7.7% LOD 0.310 +3.3% CBI 0.110 +0.0%
Other Routine +

Zentek Granted U.S. Patent for ZenGUARD(TM) Graphene-Based Technology

Zentek secured a U.S. patent for its ZenGUARD graphene technology, though commercial execution and Nasdaq compliance remain critical challenges for the company.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 11:12 ZEN · 0.68 Zentek Ltd.
Executive Summary
  • U.S. Patent No. 12,616,206 issued by the USPTO covering foundational graphene-based technology for the ZenGUARD platform.
  • Patent includes a 327-day term extension to compensate for examination delays.
  • Complements an existing Canadian patent covering ZenGUARD personal protective equipment and HVAC applications.
  • ZenGUARD Enhanced Air Filters are commercially available in Canada following a May 6, 2026 launch.
  • Company is evaluating U.S. EPA regulatory requirements while partnering with Quality Filters Inc. for potential U.S. manufacturing and distribution.
  • U.S. air filter market estimated at ~$5.3B in 2025.
  • Management explicitly notes no assurance of U.S. entry, timing, scope, or commercial success.
Material Impact
  • The patent grant is a routine, expected intellectual property milestone that strengthens the company's defensive moat but does not generate immediate revenue or alter the commercialization timeline. U.S. market entry remains strictly contingent on EPA approval, manufacturing scalability, and market acceptance. The financing closed in late May 2026 provides sufficient capital to navigate these regulatory and commercial steps. Given the company's long development history and prior regulatory updates, the market likely already priced in this IP progression.
ZEN · Price
Company Overview
  • Zentek operates three core platforms: Albany Graphite (nuclear-grade, 5N purity graphite), ZenGUARD (graphene-enhanced air filtration), and Triera Biosciences (aptamer-based diagnostics).
  • Flagship projects are the commercialization of ZenGUARD in North America and the advancement of the Albany Graphite Project toward a Preliminary Economic Assessment (PEA) and potential spin-out or strategic partnership.
  • Management under CEO Moe Jiwan (appointed Dec 2025) has implemented a strategic reset, focusing on cost reductions, winding down non-core initiatives, and tying future capital raises to specific project milestones.
Read the original news release →

More from Zentek Ltd.

Jul 07, 2026 · 09:19

Zentek secures its first US commercial order, validating its pilot program while facing a Nasdaq delisting deadline at $0.67.

M&A / Property Jun 29, 2026 · 08:01

Zentek secures U.S. licensing for its ZenGUARD filtration media as the Albany project preliminary economic assessment nears completion.

M&A / Property Jun 26, 2026 · 09:28

Zentek Forms U.S. Joint Venture to Position Its Albany Ultra-High-Purity Graphite in the North American National-Security Supply Chain

M&A / Property May 27, 2026 · 09:10

Zentek closes $18M oversubscribed financing to advance Albany graphite PEA, but stock drifts below issue price amid Nasdaq compliance pressure.

Financings May 19, 2026 · 07:31

Zentek Secures Liquidity with Oversubscribed Offering Amid Nasdaq Compliance Pressure

Financings May 14, 2026 · 16:31

Zentek Lands $15 Million Brokered Deal to Fund Albany Graphite PEA and Scale ZenGUARD's Government Adoption

Financings